Mission & Accomplishments

PathoLase, Inc. is a world-class group of professionals in the medical & biophotonic fields developing light-based technology and adjunct therapies for the treatment and identification of microbial pathogens.

We conceive, develop and license devices that provide medical specialists with safe, time and cost effective methods of prevention and resolution of diseases. Our model is based upon technological advances in lasers, fiber optic delivery systems and computer controllers.

The PinPointe FootLaser Story

In 2006, after PathoLase identified the need for a light-based protocol for onychomycosis (nail fungus), Founder, John Strisower, gathered around him an expert team who started with the basic science and research, math modeling and clinical dosimetry.

In 2008, PathoLase built the first prototype of the PinPointe™ FootLaser™ and began multi-phase clinical trials, later submitting results to the FDA and global regulatory bodies for clearance. The FootLaser became the first cleared global market leader for devices of its kind with clinically-proven results.

In September of 2011, the PinPointe FootLaser product line was spun out to (NuvoLase, Inc.) and in October of 2011, (Cynosure, Inc. NASD: CYNO) announced its acquisition of worldwide exclusive distribution rights of the PinPointe FootLaser from NuvoLase.